Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme

Next Previous
Trial Profile

Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYT 101 (Primary) ; Pembrolizumab (Primary)
  • Indications Astrocytoma; Glioblastoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TCaP

Most Recent Events

  • 07 Oct 2025 According to a Cyteph media release, phase I trial follows participants through dose-escalation cohorts, with key readouts expected at the end of Q4 2025.
  • 07 Oct 2025 According to a Cyteph media release, the Phase I study is being conducted in collaboration with Briz Brain & Spine and the Newro Foundation, and is funded through Australia's national biotech incubator CUREator.
  • 07 Oct 2025 According to a Cyteph media release, company has successfully completed recruitment for its first-in-human phase I clinical trial of CYT-101.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top